Abstract
Though the past three decades have led to a renaissance in vaccine design, the development of vaccines that protect against helminth diseases remains elusive. The need for protective vaccines for humans and livestock remains urgent because of the side-effect profiles of anti-helminthic drugs and the growing incidence of antimicrobial resistance and declining efficacy. The “-omics” era has led to renewed interest in vaccine development against helminth diseases, as candidate vaccines can now be designed, evaluated, and refined in a fraction of the time previously required. In this chapter, we describe and review genomic, transcriptomic, and proteomic approaches to the design of vaccines against helminth diseases.
Keywords
- omics
- vaccine
- proteomics
- parasitic helminth
- onchocerciasis
- lymphatic Filariasis
- soil-transmitted helminths
- schistosomiasis
1. Introduction
Parasitic helminths that cause human and veterinary diseases can be found in two phyla:
Vaccine development against helminth diseases has historically been challenging for a variety of reasons. Helminths are diploid organisms with multiple life stages that are notoriously immunomodulatory. They are able to migrate to multiple tissues and possess numerous immune evasion strategies. The combination of the transient antigen profiles and complex Type 2 immune responses have rendered efforts to immunize patients with killed organisms, attenuated organisms, or single immunogens unsuccessful [11, 12, 13]. Many experimental vaccines for ruminant helminth diseases, such as echinococcosis and fascioliasis, have been described, and a vaccine that protects sheep and goats from Barber’s pole worm (Barbervax®, developed by the Moredun Foundation) has been licensed in the United Kingdom, Australia, and South Africa. The development of Barbervax® was a lengthy process because of the technology available at the time. Additionally, Barbervax® and other experimental vaccines suffer from modest efficacy and at times complicated dosing regimens. Vaccines for human helminth diseases have yet to be licensed due to failures of traditional vaccine design approaches.
The advent of the “-omics” era has led to renewed enthusiasm for vaccine development against helminth diseases and other NTDs. Vaccines similar to Barbervax® can now be designed and modified in a fraction of the time required. Research efforts utilizing genomics, transcriptomics, and proteomics have been undertaken to identify potential antigens and evaluate their expression kinetics during infection and chronic disease as well as their potential to evolve in response to vaccinated populations. Ultimately, multi-omics approaches to vaccine design for helminth infections have the potential to address a multitude of complex factors that are involved in the host–parasite interaction, the intricacies of vaccine design, and the evolutionary implications that follow the introduction of any and all selective pressures. In this chapter, we explore genomic, transcriptomic, and proteomic approaches to the design of vaccines against helminth diseases.
2. “Omic” technologies and reverse vaccinology
Vaccine design was historically approached by manipulating whole infectious agents or their toxins, either by inactivating them or attenuating them. Next-generation vaccines (
The field of genetic and genomic studies has significantly progressed in the last few decades. Scientists have progressed from analyzing single genes and their functions to studying the entire genetic complements—genomes—of organisms. The field of pathogen genomics has facilitated the development of numerous precise diagnostics and vaccines. These vaccines almost exclusively target viral or bacterial pathogens, however [14]. While it is possible to identify potential antigens based on gene sequences, actual transcribed and translated epitopes may look vastly different, and may not elicit the expected immune response. As such, genomics alone may not be the most reliable informant of a potential vaccine target, due to variations in transcription and protein processing that take place. Section 3 of this chapter aims to review genomic approaches to vaccine development against helminth diseases and elucidate critical concepts and issues related to this approach.
As opposed to a genome, a transcriptome is a collection of all non-ribosomal RNA within a cell type, tissue, or organism under a specific set of circumstances or at a specific stage of the life cycle. The study of transcriptomics allows for the focus to be placed on gene expression throughout various steps of the life cycle and under different conditions [15]. Recently, the availability of sequencing technologies has made both genomics and transcriptomics relatively low-cost analyses that can be routinely performed in many laboratories. Transcriptomic analysis of helminths suffered from a bottleneck due to a lack of publicly available genomic databases for parasitic helminths until recently. Some of these challenges still persist, however, because helminths contain many unique sequences that have not previously been annotated with correlation to an associated protein in other organisms [16]. Additionally, transcriptomics can be used to provide insight into immunomodulation and thus vaccine interference mechanisms by being used as profiling tools to screen infected hosts. While transcriptomic analysis provides greater sensitivity in predicting potential antigens that will be expressed during infection, it cannot account for post-transcriptional regulation of protein expression or any non-canonical post-translational modifications. Section 4 of this chapter aims to review transcriptomic approaches to vaccine development against helminth diseases and elucidate critical concepts and issues related to this approach.
Thematically similar to a transcriptome, a proteome is the full complement of mature, modified proteins present under specific conditions within specific cells or tissues [17]. The proteomic analysis allows target-based approaches to parasite interventions, including the development of anti-helminth vaccines. Previously, transcriptomes of pathogens have been used to identify vaccine targets; however, proteomics allows for a greater likelihood of true representation of potential antigens present during infection. This is especially important for helminths and other parasites because protein expression varies greatly based on the life-cycle stage [18, 19]. By describing a parasitic helminth’s proteome, we can gain a better insight into antigenic targets that are present at each life stage of the parasite. Similar to transcriptomic analysis, proteomic studies of infected hosts can also aid in understanding and circumventing helminth immunomodulatory mechanisms that could adversely affect vaccine efficacy. These studies can be critical in aiding complex vaccine designs such that poor or adverse responses can be avoided. Section 5 of this chapter aims to review proteomic approaches to vaccine development against helminth diseases and elucidate critical concepts and issues related to this approach.
3. Genomic approaches to vaccine development for helminth diseases
The advent of high-throughput genome sequencing has fundamentally changed the approach to vaccine design, enabling the evaluation and fine-scale targeting of potential vaccine antigens throughout the parasite life cycle. Structural genomic, functional genomic, and epigenomic approaches allow for the identification of an estimated 10- to 100-fold more new antigens for vaccine design and drug target candidates as compared to conventional methods in the same time frame [20]. Furthermore, the completion of the Human Genome Project allows for the evaluation of potential antigens for molecular mimicry by parasites that could cause pathological responses to vaccines, and for a thorough understanding of host-pathogen interactions during active infection that could impact vaccine-derived protection [21].
The use of genome-wide applications for human vaccine development has already been observed for bacterial and viral pathogens. The complete genome sequence of
The first parasitic nematode, whose genome was sequenced, was
Despite their numerous advantages, genomic analyses have several drawbacks. Genomic analyses allow for the identification of numerous potential vaccine antigens; however, antigen target selection for vaccine development can be clouded by the immense number of options, many of which may be nonfunctional or promote regulatory responses in helminths and should be eliminated from vaccine formulations [37]. This was previously observed in the development of candidate vaccines against
4. Transcriptomic approaches to vaccine development for helminth diseases
Transcriptomic analysis with a view toward vaccine design circumvents some of the challenges posed by relying on genomic analysis alone. Traditionally, to annotate a transcriptome, the transcriptome of interest is run using a pairwise homology-based analysis with other known curated and annotated genome sequence data sets from other organisms. Initially, the transcripts and genes of parasitic helminths were not able to be annotated in this manner as they did not correlate with data that were publicly available [16]. Analysis of transcriptomic data for various parasites identified several categories of genes that encode proteins without similarity to other organisms. It is likely that these genes are exclusive to the parasite they are found in and likely play a role in parasite survival and adaptation. The uniqueness of these genes found in the transcriptome at various life stages may also provide targets for vaccine development [41]. Mangiola
The creation of annotated transcriptome databases and the relative availability of transcriptome sequencing has created an opportunity for researchers to explore the difference in gene expression across the life cycle of various helminths. Vaccine development targeting multiple life stages of many parasitic helminths can be pursued by understanding the changes in gene expression throughout the life cycle [41, 42, 43, 44, 45]. These analyses have been carried out with different species of parasitic helminths and have been able to identify differentially expressed genes throughout the life cycle related to parasite infection, survival, and immune evasion. Genes that are differentially expressed in transcriptome analysis between life-cycle stages in relation to their role in the host infection process may be relevant to the survival of the parasite and can serve as targets for vaccine development that will prevent against infectious stages, or therapeutics that will protect against pathologic life stages [42]. The importance of this is apparent with the success of Barbervax®. The complex life cycle of
Transcriptomic analysis can also be used to examine the host–parasite interactions. On the helminth side, transcriptomic analysis can identify specific gene expression patterns in locations of interest in the parasite body. For example, Foth et al described transcripts found in the anterior region of
A newer area of interest in vaccine development for parasitic helminths is the analysis of excretory/secretory products. These are various molecules released at the host–parasite interface and likely play a role in the manipulation of the host response. These products can be proteins, lipids, nucleic acids, metabolites, and extracellular vessels [51]. The microRNA (miRNA) present in extracellular vessels appears to play a role in the regulation of gene expression and immunomodulation of the host response. Understanding this miRNA will aid in identifying the ways that helminth infections are able to induce differing expressions within the host [52]. The ability of concentrated, purified versions of this miRNA may be able to be used to augment responses to subunit antigen vaccines.
Transcriptomic analysis from parasite life cycles and infected hosts is a useful tool in the development of anti-helminth vaccines. These analyses can contribute to all aspects of vaccine design, from identification of antigens to identifying (and thus circumventing) mechanisms with which parasitic helminths are able to evade adaptive immunity.
5. Proteomic approaches to vaccine development for helminth diseases
Proteomic analysis is among the most powerful tools for the identification of potential protective antigens against helminth diseases. The advent of proteomic technologies provided the opportunity not only to identify potential antigens but to detect any post-translational modifications as well. In addition, proteomic analyses identify all potential antigens, not simply those targeted by patient immune responses during infection. To ensure long-term survival, helminths tend to modulate and subdue immune responses, and the ability of these organisms to undergo host immune evasion poses a challenge for vaccine development [53]. Evaluating the adaptive immune responses of infected patients to identify potential antigens may be misleading, because these responses may be directed at non-neutralizing or variable antigens. Proteomic analyses can identify secreted proteins (
A small number of vaccines designed following proteomics, immunomics, and reverse vaccinology analyses have been described; however, few have moved into animal trials to evaluate their efficacy. Potential antigens have been identified for
6. Conclusions
Vaccines that protect against helminth diseases remain largely elusive in human and veterinary medicine. The successful licensure and deployment of the subunit vaccine Barbervax® provide evidence that the development of next-generation vaccines against parasitic helminths is an attainable goal. Multi-omic approaches allow for the design and evaluation of rationally designed subunit vaccines. The development of successful candidate vaccines has enormous potential to provide protection for the billions of people impacted by helminth diseases.
References
- 1.
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. The Lancet. 2018; 392 (10159):1789-1858 - 2.
Hotez PJ. Forgotten People, Forgotten Diseases: Neglected Tropical Diseases and their Impact on Global Health and Development. 3rd ed. Washington, DC, USA: ASM Press; 2021 - 3.
Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on infections with microbial pathogens. Nature Immunology. 2013; 14 (11):1118-1126 - 4.
Babu S, Nutman TB. Helminth-tuberculosis co-infection: An immunologic perspective. Trends in Immunology. 2016; 37 (9):597-607 - 5.
Law AE, Shears RK, Lopez Rodas AA, Grencis RK, Cooper PJ, Neill DR, et al. Intestinal helminth co-infection is an unrecognised risk factor for increased pneumococcal carriage density and invasive disease. Scientific Reports. 2021; 11 (1):6984 - 6.
Albonico M, Smith PG, Ercole E, Hall A, Chwaya HM, Alawi KS, et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1995; 89 (5):538-541 - 7.
Albonico M, Wright V, Bickle Q. Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island. Molecular and Biochemical Parasitology. 2004; 134 (2):281-284 - 8.
Geerts S, Coles GC, Gryseels B. Anthelmintic resistance in human helminths: Learning from the problems with worm control in livestock. Parasitology Today. 1997; 13 (4):149-151 - 9.
Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: The great neglected tropical diseases. Journal of Clinical Investigation. 2008; 118 (4):1311-1321 - 10.
Prabhu PR, Madhumathi J, Kaliraj P. Immunotechnological advancements in developing vaccines for lymphatic Filariasis. In: Tyagi B, editor. Lymphatic Filariasis. Singapore: Springer; 2018 - 11.
Loukas A, Giacomin P. Developments in the design of anti-helminth vaccines. In: Gause W, Artis D, editors. The Th2 Type Immune Response in Health and Disease. New York, NY: Springer; 2016 - 12.
Maizels RM, Holland MJ, Falcone FH, Zang X-X, Yazdanbakhsh M. Vaccination against helminth parasites–the ultimate challenge for vaccinologists? Immunological Reviews. 1999; 171 (1):125-147 - 13.
Maizels RM. Identifying novel candidates and configurations for human helminth vaccines. Expert Review of Vaccines. 2021; 20 (11):1389-1393 - 14.
Sautto GA, Kirchenbaum GA, Diotti RA, Criscuolo E, Ferrara F. Next generation vaccines for infectious diseases. Journal of Immunology Research. 2019; 2019 :5890962 - 15.
Dong Z, Chen Y. Transcriptomics: Advances and approaches. Science China. Life Sciences. 2013; 56 :960-967 - 16.
Mangiola S, Young ND, Korhonen P, Mondal A, Scheerlinck JP, Sternberg PW, et al. Getting the most out of parasitic helminth transcriptomes using HelmDB: Implications for biology and biotechnology. Biotechnology Advances. 2013; 31 (8):1109-1119 - 17.
Tyers M, Mann M. From genomics to proteomics. Nature. 2003; 422 :193-197 - 18.
Maizels RM, Smits HH, McSorley HJ. Modulation of host immunity by helminths: The expanding repertoire of parasite effector molecules. Immunity. 2018; 49 (5):801-818 - 19.
Rehman A, Ahmad S, Shahid F, Albutti A, Alwashmi ASS, Aljasir MA, et al. Integrated core proteomics, subtractive proteomics, and immunoinformatics investigation to unveil a potential multi-epitope vaccine against schistosomiasis. Vaccine. 2021; 9 (6):658 - 20.
Seib KL, Dougan G, Rappuoli R. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genetics. 2009; 5 (10):e1000612 - 21.
Gay CG, Zuerner R, Bannantine JP, Lillehoj HS, Zhu J, Green RB, et al. Genómica y Desarollo de Vacunas. Revue Scientifique et Technique de l'OIE. 2007; 26 (1):49-67 - 22.
Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against Serogroup B Meningococcus by whole-genome sequencing. Science. 2000; 287 (5459):1816-1820 - 23.
Welsch JA, Moe GR, Rossi R, Adu-Bobie J, Rappuoli R, Granoff DM. Antibody to genome-derived Neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. The Journal of Infectious Diseases. 2003; 188 (11):1730-1740 - 24.
Knyazev S, Chhugani K, Sarwal V, Ayyala R, Singh H, Karthikeyan S, et al. Unlocking capacities of viral genomics for the COVID-19 pandemic response. 2021;ArXiv, arXiv:2104.14005v2 - 25.
Ghedin E, Wang S, Foster JM, Slatko BE. First sequenced genome of a parasitic nematode. Trends in Parasitology. 2004; 20 (4):151-153 - 26.
Zerlotini A, Aguiar ERGR, Fudong Y, Huayong X, Li Y, Young ND, et al. SchistoDB: An updated genome resource for the three key schistosomes of humans. Nucleic Acids Research. 2013; 41 (D1):D728-D731 - 27.
Huang Y, Chen W, Wang X, Liu H, Chen Y, et al. The carcinogenic liver fluke, Clonorchis sinensis : New assembly, reannotation and analysis of the genome and characterization of tissue transcriptomes. PLoS One. 2013;8 (1):e54732 - 28.
Desjardins C, Cerqueira G, Goldberg J, et al. Genomics of Loa loa , aWolbachia -free filarial parasite of humans. Nature Genetics. 2013;45 :495-500 - 29.
Zheng H, Zhang W, Zhang L, et al. The genome of the hydatid tapeworm Echinococcus granulosus . Nature Genetics. 2013;45 :1168-1175 - 30.
Hunt V, Tsai I, Coghlan A, et al. The genomic basis of parasitism in the Strongyloides clade of nematodes. Nature Genetics. 2016;48 :299-307 - 31.
Small ST, Reimer LJ, Tisch DJ, King CL, Christensen BM, Siba PM, et al. Population genomics of the filarial nematode Parasitewuchereria bancrofti from mosquitoes. Molecular Ecology. 2016;25 (7):1465-1477 - 32.
Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, et al. GenBank. Nucleic Acids Research. 2018; 46 (D1):D41-D47 - 33.
Madeira F, Park YM, Lee J, Buso N, Gur T, Madhusoodanan N, et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Research. 2019; W1 (02):W636-W641 - 34.
Howe KL, Bolt BJ, Shafie M, Kersey P, Berriman M. WormBase parasite—a comprehensive resource for helminth genomics. Molecular and Biochemical Parasitology. 2017; 215 :2-10 - 35.
Laing R, Kikuchi T, Martinelli A, et al. The genome and transcriptome of Haemonchus contortus , a key model parasite for drug and vaccine discovery. Genome Biology. 2013;14 :R88 - 36.
Markaki M, Tavernarakis N. Modeling human diseases in Caenorhabditis elegans . Biotechnology Journal. 2010;5 (12):1261-1276 - 37.
Hewitson JP, Maizels RM. Vaccination against helminth parasite infections. Expert Review of Vaccines. 2014; 13 (4):473-487 - 38.
Carvalho GB, Silva-Pereira RA, Pacífico LG, Fonseca CT. Identification of Schistosoma mansoni candidate antigens for diagnosis of schistosomiasis. Memórias do Instituto Oswaldo Cruz. 2011;106 (7):837-843 - 39.
Carvalho GB, Pacífico LG, Pimenta DL, Siqueira LM, Teixeira-Carvalho A, Coelho PM, et al. Evaluation of the use of C-terminal part of the Schistosoma mansoni 200kda tegumental protein in schistosomiasis diagnosis and vaccine formulation. Experimental Parasitology. 2014;139 :24-32 - 40.
Riveau G, Schacht AM, Dompnier JP, Deplanque D, Seck M, et al. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: A phase 3 randomized, controlled trial in Senegalese children. PLoS Neglected Tropical Diseases. 2018; 12 (12):e0006968 - 41.
Farias LP, Tararam CA, Miyasato PA, et al. Screening the Schistosoma mansoni transcriptome for genes differentially expressed in the schistosomulum stage in search for vaccine candidates. Parasitology Research. 2011;108 :123-135 - 42.
Marcilla A, Garg G, Bernal D, et al. The transcriptome analysis of Strongyloides stercoralis L3i larvae reveals targets for intervention in a neglected disease. PLoS Neglected Tropical Diseases. 2012;6 (2):e1513 - 43.
Laing R, Kikuchi T, Martinelli A, et al. The genome and transcriptome of Haemonchus contortus , a key model parasite for drug and vaccine discovery. Genome Biology. 2013;14 (8):R88 - 44.
Schwarz EM, Korhonen PK, Campbell BE, et al. The genome and developmental transcriptome of the strongylid nematode Haemonchus contortus . Genome Biology. 2013;14 (8):R89 - 45.
Zhang S. Comparative transcriptomic analysis of the larval and adult stages of Taenia pisiformis . Genes. 2019;10 (7):507 - 46.
Kabagambe EK, Barras SR, Li Y, Peña MT, Smith WD, Miller JE. Attempts to control haemonchosis in grazing ewes by vaccination with gut membrane proteins of the parasite. Veterinary Parasitology. 2000; 92 (1):15-23 - 47.
Smith WD, Smith SK, Pettit D. Evaluation of immunization with gut membrane glycoproteins of Ostertagia ostertagi against homologous challenge in calves and against Haemonchus contortus in sheep. Parasite Immunology. 2000;22 (5):239-247 - 48.
Foth BJ, Tsai IJ, Reid AJ, et al. Whipworm genome and dual-species transcriptome analyses provide molecular insights into an intimate host-parasite interaction. Nature Genetics. 2014; 46 (7):693-700 - 49.
Mangiola S, Young ND, Sternberg PW, et al. Analysis of the transcriptome of adult Dictyocaulus filaria and comparison withDictyocaulus viviparus , with a focus on molecules involved in host-parasite interactions. International Journal of Parasitology. 2014;44 (3-4):251-261 - 50.
Naranjo-Lucena A, Correia CN, Molina-Hernández V, et al. Transcriptomic analysis of ovine hepatic lymph node following Fasciola hepatica infection–inhibition of NK cell and IgE-mediated Signaling. Frontiers in Immunology. 2021;12 :687579 - 51.
Sánchez-López CM, Trelis M, Bernal D, Marcilla A. Overview of the interaction of helminth extracellular vesicles with the host and their potential functions and biological applications. Molecular Immunology. 2021; 134 :228-235 - 52.
Tritten L, Geary TG. Helminth extracellular vesicles in host-parasite interactions. Current Opinion in Microbiology. 2018; 46 :73-79 - 53.
Robinson MW, Cwiklinski K. Proteomics of host-helminth interactions. Pathogens. 2021; 10 (10):1317 - 54.
Garg G, Ranganathan S. Helminth secretome database (HSD): A collection of helminth excretory/secretory proteins predicted from expressed sequence tags (ESTs). BMC Genomics. 2012; 13 (7):S8 - 55.
Neves LX, Wilson RA, Brownridge P, Harman VM, Holman SW, Beynon RJ, et al. Quantitative proteomics of enriched Esophageal and gut tissues from the human blood fluke. Journal of Proteome Research. 2020; 19 (1):314-326 - 56.
Kaur R, Arora N, Rawat SS, Keshri AK, Singh N, Show SK, et al. Immunoinformatics driven construction of multi-epitope vaccine candidate against. Expert Review of Vaccines. 2021; 20 (12):1637-1649 - 57.
Montaño KJ, Cuéllar C, Sotillo J. Rodent models for the study of soil-transmitted helminths: A proteomics approach. Frontiers in Cellular and Infection Microbiology. 2021; 11 :639573 - 58.
Culma MF. Strongyloides stercoralis proteome: A reverse approach to the identification of potential immunogenic candidates. Microbial Pathogenesis. 2021;152 :104545 - 59.
Kaur R, Arora N, Jamakhani MA, Malik S, Kumar P, Anjum F, et al. Development of multi-epitope chimeric vaccine against. Expert Review of Vaccines. 2020; 19 (1):105-114 - 60.
Salazar Garcés LF, Santiago LF, Santos SPO, Jaramillo Hernández DA, da Silva MB, Alves VDS, et al. Immunogenicity and protection induced by recombinant Toxocara canis proteins in a murine model of toxocariasis. Vaccine. 2020;38 (30):4762-4772 - 61.
Devoe NC, Corbett IJ, Barker L, Chang R, Gudis P, Mullen N, et al. Differential evolutionary selection and natural evolvability observed in ALT proteins of human filarial parasites. PLoS One. 2016; 11 (2):e0148611 - 62.
Miles S, Portela M, Cyrklaff M, Ancarola ME, Frischknecht F, Durán R, et al. Combining proteomics and bioinformatics to explore novel tegumental antigens as vaccine candidates against Echinococcus granulosus infection. Journal of Cellular Biochemistry. 2019;120 (9):15320-15336 - 63.
Pourseif MM, Moghaddam G, Saeedi N, Barzegari A, Dehghani J, Omidi Y. Current status and future prospective of vaccine development against Echinococcus granulosus . Biologicals. 2018;51 :1-11 - 64.
McCusker P, Toet H, Rathinasamy V, Young N, Beddoe T, Anderson G, et al. Molecular characterisation and vaccine efficacy of two novel developmentally regulated surface tegument proteins of Fasciola hepatica . Veterinary Parasitology. 2020;286 :109244 - 65.
Matthews JB, Geldhof P, Tzelos T, Claerebout E. Progress in the development of subunit vaccines for gastrointestinal nematodes of ruminants. Parasite Immunology. 2016; 38 (12):744-753 - 66.
Geldhof P, Vercauteren I, Vercruysse J, Knox DP, Van Den Broeck W, Claerebout E. Validation of the protective Ostertagia ostertagi ES-thiol antigens with different adjuvantia. Parasite Immunology. 2004;26 (1):37-43 - 67.
Nisbet AJ, McNeilly TN, Wildblood LA, Morrison AA, Bartley DJ, Bartley Y, et al. Successful immunization against a parasitic nematode by vaccination with recombinant proteins. Vaccine. 2013; 31 (37):4017-4023